Freeman Chris, an insider at Guardant Health Inc (GH), sold 28,951 shares of the company's stock on December 4, 2025, at a price of $105.99 per share, totaling $3.07 million. Following this transaction, Chris retains 28,951 shares in the company.
Guardant Health, headquartered in Palo Alto, California, is a precision oncology firm that specializes in cancer treatment through proprietary blood-based tests and advanced analytics. The company went public on October 4, 2018, and currently has a market capitalization of $12.1 billion. Its EPS (TTM) stands at -3.21.
The move underscores the importance of monitoring insider transactions, which are reported to the SEC for transparency. While insider selling can occur for various reasons, including diversification or personal financial needs, it does not inherently indicate negative sentiment towards the company. Investors are encouraged to analyze trends in insider activity across multiple individuals and timeframes, rather than focusing on isolated transactions.
Guardant Health is set to report its next earnings on April 28, 2026, with an estimated EPS of -0.66 and revenue of $279.1 million. The following report is scheduled for July 28, 2026, with an EPS estimate of -0.61 and revenue expected at $304.5 million.